Skip to content
Study details
Enrolling now

Axitinib and Ipilimumab for Advanced Melanoma

H. Lee Moffitt Cancer Center and Research Institute
NCT IDNCT04996823ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

25

Study length

about 5.7 years

Ages

18+

Locations

1 site in FL

What this study is about

This trial is testing if taking axitinib with ipilimumab is effective in treating advanced melanoma. The treatment involves medication. Adults will be enrolled, and its length is 2063 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Axitinib
  • 2.Take Ipilimumab

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

axitinib, ipilimumab (Immune checkpoint inhibitor; blocks CTLA-4 on T cells)

Drug routes

oral (Oral Tablet), injection (Injection)

Endpoints

Primary: Overall Response Rate

Secondary: Clinical Benefit Rate, Duration of Response, Overall Survival, Progression Free Survival

Body systems

Oncology